gene_symbol
CD19
hgnc_id
HGNC:1633
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
DIRECT
cytotoxicity_mechanism
Blinatumomab bridges CD3+ T cells to CD19+ cells, activating T-cell cytotoxicity and perforin/granzyme-mediated killing of CD19-expressing targets.
enzyme_product
Off
epitope
On
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
B-cell surface antigen
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06504186
disease_id_num_tar_ref
5072
drug_id_num_tar_ref
13715